阿帕替尼治疗53例晚期原发性肝癌的疗效
| 作者: |
1宋锦添,
1陈奕贵,
2许春伟,
1蔡雄超,
1陈丽珠
1 福建医科大学附属福建省肿瘤医院消化道肿瘤内科，福州 350014 2 福建医科大学附属福建省肿瘤医院病理科，福州 350014 |
| 通讯: |
陈奕贵
Email: 1148534431@qq.com 许春伟 Email: xuchunweibbb@163.com |
| DOI: | 10.3978/j.issn.2095-6959.2017.03.019 |
| 基金: | 国家临床重点专科建设项目, 2013 |
摘要
目的：探讨阿帕替尼治疗晚期原发性肝癌的疗效及安全性。方法：回顾性分析经过多程治疗后晚期原发性肝癌(primary liver cancer，PLC)53例，每天给予阿帕替尼250，500，850 mg口服治疗，直至肿瘤进展或者不能耐受。随访时间21个月，评估疗效并观察药物毒副作用。结果：本组53例患者均能进行疗效评价。客观缓解率(objective response rate，ORR)为18.86%，疾病控制率(disease control rate，DCR)为56.6%，中位无进展生存时间(median progress-free survival，mPFS)为3.65个月。不良反应主要为高血压、手足综合征、蛋白尿、疲乏等，多数为Ⅰ级或Ⅱ级，多数患者能够能耐受。结论：阿帕替尼对晚期原发肝癌安全、有效，且不良反应多能耐受。
关键词：
阿帕替尼
原发肝癌
安全
有效
Effect of apatinib on treatment of 53 cases of advanced primary liver cancer
CorrespondingAuthor: CHEN Yigui Email: 1148534431@qq.com
DOI: 10.3978/j.issn.2095-6959.2017.03.019
Abstract
Objective: To evaluate the curative effect and safety of apatinib on treatment of advanced primary liver cancer. Methods: Fifty-three patients of advanced primary liver cancer with much routine treatment were enrolled in the group. All the patients were randomly divided into the orally took apatinib 250, 500, 850 mg until the disease progressed or the patients could not tolerate. Efficacy and drug toxicity was observed after 21 months followed-up. Results: Response was assessed in all the 53 patients. The objective response rate (ORR) was 18.86% and the disease control rate (DCR) was 56.6%. The main adverse reactions were hypertension, hand-foot syndrome, proteinuria, fatigue, mostly degree Ⅰor Ⅱ, most of the patients tolerated. Conclusion: Apatinib is an effective drug for the treatment of advanced primary liver cancer, with an advantage of nice durability.